-
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects
16 Oct 2025 18:18 GMT
… HFrEF. Among these, Omecamtiv Mecarbil is the most extensively studied … without increasing intracellular calcium, Omecamtiv Mecarbil improves cardiac function through … therapeutic positioning relative to Omecamtiv Mecarbil and standard heart failure …
-
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 12:30 GMT
… the trial. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, … has shown that omecamtiv mecarbil increases cardiac contractility … omecamtiv mecarbil, demonstrated a statistically significant effect of treatment with omecamtiv mecarbil …
-
Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: Withdrawn application
31 May 2024 14:36 GMT
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …
-
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
29 Sep 2025 11:30 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
24 Sep 2025 11:30 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in … , Facebook and YouTube. Disclaimer Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are …
-
HFSA 2025 Preview: 8 Late-Breaking Studies to Know
24 Sep 2025 06:36 GMT
… to first-generation myosin activator omecamtiv mecarbil in patients with heart failure …
-
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
23 Sep 2025 20:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
FDA Declines Approval for Omecamtiv Mecarbil in HFrEF
01 Mar 2023 20:08 GMT
… advisers recommended against approval of omecamtiv mecarbil for chronic HFrEF, as reported … by theheart.org | Medscape Cardiology, omecamtiv mecarbil produced a positive result for … an additional clinical trial of omecamtiv mecarbil are required to establish …
-
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
28 Feb 2023 22:31 GMT
… Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, … access the call. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, selective, … research has shown that omecamtiv mecarbil increases cardiac contractility without …
-
FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure
14 Dec 2022 21:19 GMT
… has recommended against approval of omecamtiv mecarbil (Cytokinetics) for the treatment of … reduced ejection fraction (HFrEF).
Omecamtiv mecarbil is a first-in-class … by theheart.org | Medscape Cardiology, omecamtiv mecarbil produced a positive result for …